Products and services for diversifying preclinical models
AMSBIO has expanded its range of products and services dedicated to assisting scientists diversify their preclinical models effectively
7 Mar 2024
Industry news
AMSBIO discusses the use of a proposed intestinal organoid biobank to combat accessibility issues as well as raising the issues of the lack of reporting by gender in COVID-19 vaccine development, where women had a disproportionate number of adverse-effects, under-reported due to aggregated data.
Until 1993, most clinical trial participants were men of European descent, leading to a lack of data on the safety and efficacy of treatments for women and diverse populations. Although attitudes in clinical trials are changing, inclusivity in preclinical research is still often overlooked, leading to critical gaps in the understanding of how drugs and treatments affect different populations even before they proceed to human trials.
AMSBIO is a global provider of human and animal biospecimens to help increase diversity in research. The company’s extensive biorepository houses an array of tissues from reliable sources, including a comprehensive selection of healthy tissues as well as a variety of disease states from different genders and ethnicities.
For specific research needs, AMSBIO additionally offers a custom tissue procurement service to supply the samples to match your research demands, however complex the donor demographics required. In addition, leveraging a combination of novel organoids with proprietary lab-on-a-chip technology – AMSBIO is uniquely placed to help preclinical researchers cost effectively develop high throughput data-rich assays.